Opendata, web and dolomites

mtFOIE GRAS SIGNED

mitoFOIE GRAS: Non-invasive Profiling of Mitochondrial Function in Non-Alcoholic Fatty Liver Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 mtFOIE GRAS project word cloud

Explore the words cloud of the mtFOIE GRAS project. It provides you a very rough idea of what is the project "mtFOIE GRAS" about.

treatable    pathologic    french    alcoholic    unfit    costly    besides    carcinoma    multidisciplinary    surface    unmet    liver    population    steatohepatitis    mention    fat    basic    mt    scientific    rapid    hepatocellular    innovative    consequence    biopsy    killer    nafld    untreated    silent    envisages    follow    foie    training    intervention    staging    share    nash    public    team    treatment    cirrhosis    pressing    gras    students    excellent    mitochondrial    therapeutic    culminating    biomarkers    tools    worldwide    mtfoie    symptoms    staff    procedure    advocacy    chronic    mechanisms    rd    37    dysfunction    accurate    clinical    mediator    longer    phd    pathogenic    skills    risky    stages    excellence    translational    commercialization    medical    endow    exists    diagnosing    drivers    proposes    pathogenesis    plan    creation    technicians    building    synergistically    transferable    experts    routine    intersectoral    somewhat    strategy    invasive    consensus    informative    disease    central    fatty    cooperation    chain    expertises    brings   

Project "mtFOIE GRAS" data sheet

The following table provides information about the project.

Coordinator
CENTRO DE NEUROCIENCIAS E BIOLOGIACELULAR ASSOCIACAO 

Organization address
address: UNIVERSIDADE DE COIMBRA, LARGO DE POMBAL
city: COIMBRA
postcode: 3004 517
website: www.cnbc.pt

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Project website http://www.projectrisefoiegras.eu/
 Total cost 454˙500 €
 EC max contribution 454˙500 € (100%)
 Programme 1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
 Code Call H2020-MSCA-RISE-2016
 Funding Scheme MSCA-RISE
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2021-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRO DE NEUROCIENCIAS E BIOLOGIACELULAR ASSOCIACAO PT (COIMBRA) coordinator 94˙500.00
2    ASSOCIACAO PROTECTORA DOS DIABETICOS DE PORTUGAL PT (LISBOA) participant 63˙000.00
3    UNIVERSITA DEGLI STUDI DI BARI ALDO MORO IT (BARI) participant 54˙000.00
4    CONSIGLIO NAZIONALE DELLE RICERCHE IT (ROMA) participant 49˙500.00
5    KING'S COLLEGE LONDON UK (LONDON) participant 40˙500.00
6    MEDIAGNOST GESELLSCHAFT FUR FORSCHUNG UND HERSTELLUNG VON DIAGNOSTIKA GMBH DE (REUTLINGEN) participant 40˙500.00
7    UNIVERSIDADE DO PORTO PT (PORTO) participant 36˙000.00
8    AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS ES (MADRID) participant 13˙500.00
9    Faculdade de Farmácia da Universidade de Lisboa PT (Lisboa) participant 13˙500.00
10    HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH DE (NEUHERBERG) participant 13˙500.00
11    INSTYTUT BIOLOGII DOSWIADCZALNEJ IM. M. NENCKIEGO POLSKIEJ AKADEMII NAUK PL (WARSZAWA) participant 13˙500.00
12    OROBOROS INSTRUMENTS GmbH AT (INNSBRUCK) participant 13˙500.00
13    MICRO-BIOLYTICS GMBH DE (ESSLINGEN AM NECKAR) participant 9˙000.00

Map

 Project objective

'Non-Alcoholic Fatty Liver Disease (NAFLD), including its more pathologic consequence, non-alcoholic steatohepatitis (NASH), is believed to be the most common chronic liver disease worldwide, affecting between 6 to 37% of the population. NAFLD is a so called ‘silent killer’, as clinical symptoms only surface at late stages of the disease, when it is no longer treatable: untreated, NAFLD/NASH can lead to cirrhosis and hepatocellular carcinoma, culminating in liver failure. Currently the best method of diagnosing and staging the disease is liver biopsy, a costly, invasive and somewhat risky procedure, not to mention unfit for routine assessment. Besides, no therapeutic consensus exists for NAFLD/NASH treatment. mtFOIE GRAS (Foie Gras being French for 'fat liver') proposes to address the pressing need for non-invasive, accurate, rapid assessment of NAFLD/NASH stages, before and after intervention, through the development of biomarkers and innovative tools to follow mitochondrial (mt) dysfunction, a central mediator of fatty liver disease pathogenesis. This promising R&D strategy will also bring new knowledge about the disease mechanisms and improved understanding of the pathogenic process and disease drivers. To that end, mtFOIE GRAS envisages a training-through-work plan that brings together an intersectoral, multidisciplinary team of researchers and technicians experts in their fields, from basic to translational research, clinical practice, technology commercialization and public advocacy. Together with several PhD students, the team will share expertises and work synergistically along the value creation chain to address the unmet medical need of more informative NAFLD assessment. In the process, mtFOIE GRAS will endow the involved staff with excellent scientific knowledge and transferable skills while building and strengthening intersectoral cooperation among partners, thus contributing to EU RD&I excellence.'

 Deliverables

List of deliverables.
Pinpointed putative novel biomarkers and advanced methodologies. Documents, reports 2019-10-28 17:53:19
Project Website and social media Websites, patent fillings, videos etc. 2019-07-18 21:32:54

Take a look to the deliverables list in detail:  detailed list of mtFOIE GRAS deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Nádia Duarte, Inês Coelho, Denys Holovanchuk, Joana Inês Almeida, Carlos Penha-Gonçalves, Maria Paula Macedo
Dipeptidyl Peptidase-4 Is a Pro-Recovery Mediator During Acute Hepatotoxic Damage and Mirrors Severe Shifts in Kupffer Cells
published pages: 1080-1094, ISSN: 2471-254X, DOI: 10.1002/hep4.1225
Hepatology Communications 2/9 2019-07-18
2019 Ignazio Grattagliano, Liliana P. Montezinho, Paulo J. Oliveira, Gema Frühbeck, Javier Gómez-Ambrosi, Fabrizio Montecucco, Federico Carbone, Mariusz R. Wieckowski, David Q.-H. Wang, Piero Portincasa
Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease
published pages: 34-45, ISSN: 0006-2952, DOI: 10.1016/j.bcp.2018.11.020
Biochemical Pharmacology 160 2019-07-18
2018 Inês C.M. Simões, Adriana Fontes, Paolo Pinton, Hans Zischka, Mariusz R. Wieckowski
Mitochondria in non-alcoholic fatty liver disease
published pages: 93-99, ISSN: 1357-2725, DOI: 10.1016/j.biocel.2017.12.019
The International Journal of Biochemistry & Cell Biology 95 2019-07-18

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MTFOIE GRAS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MTFOIE GRAS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.3.)

TREND (2019)

Transition with Resilience for Evolutionary Development

Read More  

ROVER (2020)

RELIABLE TECHNOLOGIES AND MODELS FOR VERIFIED WIRELESS BODY-CENTRIC TRANSMISSION AND LOCALIZATION

Read More  

MAIL (2019)

Identifying Marginal Lands in Europe and strengthening their contribution potentialities in a CO2sequestration strategy

Read More